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retrospective study of surveillance, epidemiology,
and end-results population-based data
Qingguo Li†, Yuwei Wang†, Guoxiang Cai, Dawei Li and Sanjun Cai*Abstract
Background: Colon cancer with lymph node metastases has been considered as advanced stage and to have poor
survival. We postulated that patients with solitary lymph node metastasis are a distinct subset with better colon
cancer-specific survival than those with multiple lymph node metastases.
Methods: In this retrospective study, we searched Surveillance, Epidemiology, and End-Results (SEER) population-based
data and identified 86,674 patients who had been diagnosed with colon cancer without distant metastases and with
less than three metastatic nodes between 1991 and 2005. We divided lymph node status into three subgroups: pN0,
pN1a, and pN1b and obtained 5-year colon cancer-specific survival for each pT stage. We used Kaplan–Meier and
multivariate Cox regression models to assess correlations between risk factors and survival outcomes.
Results: Analysis of SEER data confirmed that patients with solitary lymph node metastases had better 5-year
cancer-specific survival than pN1b according to both univariate and multivariate analysis. This finding was
confirmed by further analyses in five pT subgroups. Cancer-specific survival of patients with pT1-2N1a was comparable
to that of those with pIIA but higher than those with pIIB. In addition, survival of patients with pT3-4aN1a was better
than those with pIIC.
Conclusion: Colon cancer patients with solitary lymph node metastasis are a distinct subset with a favorable prognosis;
full consideration should be given to this in clinical practice.
Keywords: Colon Cancer, Lymph node metastasis, Surgery, Survival analysisBackground
Colorectal cancer (CRC), one of the commonest malig-
nancies, is the third leading cause of cancer-related deaths
in the United States [1]. The incidence of CRC in Asian
countries is increasing rapidly and is likely similar to that
in Western countries [2,3]. In China, both the incidence
and mortality rate of CRC are increasing [4]. Surgical re-
section remains the mainstay of treatment of local and re-
gional disease. Lymphadenectomy, a critical component of
surgical procedures for patients with CRC, is performed* Correspondence: caisanjun_sh@163.com
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unless otherwise stated.with the aim of achieving complete resection of lesions.
In 2000, the National Comprehensive Cancer Network
(NCCN) recommended pathologic examination of at
least 12 lymph nodes (LNs) in the staging of colon can-
cer (CC). The number of metastatic LNs has been iden-
tified as an independent prognostic factor [5-7]. In the
seventh edition of the American Joint Committee on
Cancer (AJCC) Cancer Staging Manual for CC, N1 le-
sions were subdivided into N1a (solitary LN metastasis,
SLNM) and N1b (2–3 positive LNs); however, in the
current staging system N1a and N1b have been com-
bined. Patients with SLNM might be a distinct subset of
those with involved LNs, a subset without the high inci-
dence of systematic disease and poor prognosis of pa-
tients with multiple metastases in LNs. In this study, wehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Results (SEER) registries to analyze the role of SLNM in
the long-term survival of patients with CC and to assess
the appropriateness of the N1 classification in the sev-
enth edition of the TNM staging system.
Methods
The current SEER database consists of 17 population-based
cancer registries that represent approximately 28% ofTable 1 Characteristics of patients from SEER Database by LN
Total N0
Characteristic (n = 86674) (n = 61696)
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No. of LNs dissected
<12 47920 34671
≥12 38754 27025the population of the United States. The SEER data
contain no identifiers and are publicly available for
studies of cancer-based epidemiology and health policy.
The National Cancer Institute’s SEER*Stat software
(Surveillance Research Program, National Cancer Institute
SEER*Stat software, www.seer.cancer.gov/seerstat) was used
to identify patients who received a pathologic diagnosis of
adenocarcinoma, mucinous adenocarcinoma, or signet-ring
carcinoma of the CC (C18.0–19.9) between 1991 and 2005.involvement
N1a N1b P value
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current study due to the available information for cause
specific survival analysis in SEER database. Patients diag-
nosed after 2006 were excluded to ensure adequate dur-
ation of follow-up. Other exclusion criteria were as follows:
incomplete TNM staging, no LNs examined pathologically,
more than three LNs with metastases (N2), synchronous
distant metastases, patients who had died within 30 days of
surgery, and age younger than 18 or older than 80 years.
This study is based on public data from the SEER
database: we obtained permission to access the research
data files in the SEER program (reference number
12768-Nov2012). Because this study did not involve
interaction with human subjects or use personal identi-
fying information, informed consent was not required.
The study was approved by the Review Board of Fudan
University, Shanghai Cancer Center, Shanghai, China.
Ethics statement
This study was conducted in compliance with the Helsinki
Declaration. Permission to access the research data files inFigure 1 Survival curves in CC patients according to lymph node stat
χ2 = 263.886, P < 0.001. (b) pT1 stage: N0 vs. N1a, χ2 = 53.979, P < 0.001; N1a
P < 0.001; N1a vs. N1b, χ2 = 5.597, P = 0.02. (d) pT3 stage: N0 vs. N1a, χ2 = 37
vs. N1a, χ2 = 420.664, P < 0.001; N1a vs. N1b, χ2 = 71.364, P < 0.001. (f) pT4b stathe SEER program was obtained (reference number
12768-Nov2012).
Statistical analysis
Age, sex, race, extent of primary tumor invasion, total
number of LNs examined, number of involved LNs,
tumor grade, histological type of tumor, survival time,
and cause of death were retrieved from the SEER data-
base. All cases were restaged based on the AJCC-7
guidelines. The primary endpoint of this study, colon
cancer cause-specific survival (CCSS), was calculated
from the date of diagnosis to the date of cause-specific
death. Deaths attributed to the cancer of interest were
treated as events and deaths from other causes as cen-
sored observations.
χ2 tests were used to test independence, and Student’s
t-test to compare continuous data between the three
groups (pN0, pN1a, and pN1b). Exact 95% confidence
intervals (CIs) for proportions were calculated. Survival
curves were generated using Kaplan–Meier estimates;
differences between the curves were analyzed by the log-us. (a) pT1-4 stage N0 vs. N1a, χ2 = 1762.258, P < 0.001; N1a vs. N1b,
vs. N1b, χ2 = 21.414, P < 0.001. (c) pT2 stage: N0 vs. N1a, χ2 = 101.579,
4.208, P < 0.001; N1a vs. N1b, χ2 = 86.490, P < 0.001. (e) pT4a stage: N0
ge: N0 vs. N1a, χ2 = 94.180, P < 0.001; N1a vs. N1b, χ2 = 10.257, P = 0.001.
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to analyze correlations between risk factors and survival
outcomes in T1-4 N0-1b patients. All statistical analyses
were performed with the statistical software package
SPSS for Windows, version 17 (SPSS, Chicago, IL, USA).
Statistical significance was set at two-sided P < 0.05.
Results
Impact of SLNM on CC survival outcomes
We identified 86,674 eligible patients over the 15 years
covered by the study. These comprised 61,696 patients
with no LN metastases, 12,416 with SLNM, and 12,562
with two or three LN metastases. Relevant patient
characteristics and pathological features are summa-
rized in Table 1. LN status was correlated with age,Table 2 Univariate and multivariate survival analyses by pN s
Univa
Variable 5-year CCS Log rank χ2 t
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aOther includes American Indian/Alaska native, Asian/Pacific Islander, and unknown
NI: not included in multivariate survival analyses.race, pathological grading, histological type of tumor,
number of LNs dissected, and pT stage.
The median duration of follow-up was 85 months
(range 54–121 months) and the overall 5-year CCSS was
83.0%. The 5-year CCSS of pN0 patients, patients with
pN1a and patients with pN1b stage was 88.3% ± 0.1%,
74.6% ± 0.4%, and 65.1% ± 0.4%, respectively (P < 0.001).
There were significant differences in survival between pN0
patients and those with SLNM (P < 0.001), between pa-
tients with SLNM and with pN1b (P < 0.001), and between
patients with pN0 and pN1b (P < 0.001). We then made a
further comparison by pT stages and found significant dif-
ferences between all five of them (P < 0.05) (Figure 1).
According to univariate and multivariate survival ana-
lyses, pT stage, year of diagnosis, patient age, race, andtage in patients with pT1 stage CC
riate analysis Multivariate analysis
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http://www.biomedcentral.com/1471-2407/14/368LN status were significantly associated with CCSS in all
patients. pT2-4a stage female patients had better CCSS
than male patients. Tumor grade was an independent
factor for CCSS in patients with pT1 and pT3-4b. Except
in patients with pT1 stage, the number of LNs dissected
was significantly associated with CCSS according to both
univariate and multivariate survival analysis. However,
histological type of tumor was not a prognostic factor
according to both univariate and multivariate survival
analyses (Tables 2, 3, 4, 5 and 6).
Comparison of CCSS between patients with pT1-4aN1a
and those with pII stage CC
As presented in Tables 2, 3, 4, 5 and 6, the 5-year CCSS
of patients with pIIA, pIIB, and pIIC CC were 88.40%,Table 3 Univariate and multivariate survival analyses by pN s
Univa
Variable 5-year CCS Log rank χ2 t
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aOther includes American Indian/Alaska native, Asian/Pacific Islander, and unknown
NI: not included in multivariate survival analyses.82.70%, and 60.60%, respectively, all being lower than
that of those with pT1N1a (92.60%). The 5-year CCSS of
patients with pIIB and pIIC CC was lower than that of
those with pT2N1a (87.20%) and that of patients with pIIC
lower than that of those with pT3N1a (69.90%). According
to AJCC-7 T classification in stage III, we made statistical
comparison among pIIA-C, pT1-2N1a, pT1-2N1b, pT3-
4aN1a, pT3-4aN1b, pT4bN1a and pT4bN1b to know
whether there were significant differences in CCSS. Ac-
cording to multivariate analysis, the CCSS of patients with
pT1-2N1a was similar to that of those with pIIA stage dis-
ease (HR, 0.937; 95% CI, 0.838–1.049; P = 0.259, using
pIIA stage as the reference). Patients with stage pIIB dis-
ease had lower 5-year CCSS than those with pT1-2N1a
(HR, 0.677; 95% CI, 0.606–0.757; P < 0.001, using stagetage in patients with pT2 stage CC
riate analysis Multivariate analysis

























Table 4 Univariate and multivariate survival analyses by pN stage in patients with pT3 stage CC
Univariate analysis Multivariate analysis
Variable 5-year CCS Log rank χ2 test P HR (95% CI) P
Years of diagnosis 39.995 <0.001 <0.001
1988-1993 80.3% Reference
1994-1999 82.6% 0.874 (0.808-0.946)
2000-2003 84.6% 0.820 (0.763-0.881)
Sex 25.387 <0.001 <0.001
Male 82.7% Reference
Female 84.3% 0.855 (0.811-0.901)
Age 169.293 <0.001 <0.001
<60 87.3% Reference
≥60 81.7% 1.542 (1.453-1.638)
Race 103.809 <0.001 <0.001
White 84.1% Reference
Black 77.7% 1.461 (1.355-1.574)
Othera 86.2% 0.801 (0.733-0.896)
Grade 15.823 <0.001 0.032
High/moderate 84.0% Reference
Poor/anaplastic 80.8% 1.098 (1.024-1.178)
Unknown 83.5% 1.003 (0.851-1.182)
Histotype 1.212 0.271 NI
Adenocarcinoma 83.5%
Mucinous/signet ring cell 83.8%
No. of LNs dissected 270.983 <0.001 <0.001
<12 80.0% Reference
≥12 86.8% 0.668 (0.633-0.705)
LNs status 1209.713 <0.001 <0.001
N0 (pIIA) 88.4% 0.510 (0.476-0.546)
N1a 77.8% Reference
N1b 69.4% 1.449 (1.334-1.561)
aOther includes American Indian/Alaska native, Asian/Pacific Islander, and unknown.
NI: not included in multivariate survival analyses.
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with pT1-2N1b disease (HR, 0.971; 95% CI, 0.861–1.096;
P = 0.634). Patients with stage pIIC disease had significantly
lower 5-year CCSS than those with pT1-2N1a (HR, 0.254;
95% CI, 0.224–0.287; P < 0.001, using stage pIIC as the ref-
erence) and those with pT3-4aN1a (HR, 0.601; 95% CI,
0.560–0.645; P < 0.001), but higher 5-year CCSS than those
with pT4bN1a disease (HR, 1.761; 95% CI, 1.576–1.966;
P < 0.001) (Table 7).
Discussion
LN metastasis is a critical predictor of disease recur-
rence and CCSS, and therefore an important determinant
of postoperative therapy [8]. Various variables, includingpathological tumor stage, tumor grade, and degree of differ-
entiation, have been identified as being associated with LN
metastases [9,10]. In this study, we found that patients’ age,
race, pathological grading, histological type of tumor, pT
stage and number of LNs dissected provided risk stratifica-
tion for patients with LN metastasis. Tumors with solitary
positive node always mean more deep tumors and worsen
grading than those with negative LNs, and the seventh edi-
tion of the AJCC Cancer Staging Manual for colon classi-
fied any pT stage with solitary positive node into pIII or
pIV, both which means worsen survival outcomes.
Patients with esophageal cancer and SLNM have been
considered a distinct prognostic subgroup with cancer out-
comes closer to that of patients with node-negative disease
Table 5 Univariate and multivariate survival analyses by pN stage in patients with pT4a stage CC
Univariate analysis Multivariate analysis
Variable 5-year CCS Log rank χ2 test P HR (95% CI) P
Years of diagnosis 61.405 <0.001 <0.001
1988-1993 72.8% Reference
1994-1999 77.1% 0.836 (0.792-0.883)
2000-2003 77.8% 0.848 (0.803-0.896)
Sex 35.224 <0.001 <0.001
Male 75.1% Reference
Female 77.2% 0.859 (0.822-0.898)
Age 136.610 <0.001 <0.001
<60 79.9% Reference
≥60 74.5% 1.383 (1.316-1.454)
Race 85.397 <0.001 <0.001
White 76.7% Reference
Black 69.1% 1.357 (1.270-1.450)
Othera 79.7% 0.845 (0.777-0.918)
Grade 52.978 <0.001 0.032
High/moderate 77.3% Reference
Poor/anaplastic 71.5% 1.178 (1.116-1.244)
Unknown 75.5% 1.053 (0.917-1.210)
Histotype 0.011 0.915 NI
Adenocarcinoma 76.2%
Mucinous/signet ring cell 76.0%
No. of LNs dissected 266.370 <0.001 <0.001
<12 72.4% Reference
≥12 80.4% 0.708 (0.676-0.740)
LNs status 1213.378 <0.001 <0.001
N0 (pIIB) 82.7% 0.559 (0.528-0.592)
N1a 69.9% Reference
N1b 61.7% 1.317 (1.239-1.401)
aOther includes American Indian/Alaska native, Asian/Pacific Islander, and unknown.
NI: not included in multivariate survival analyses.
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has even been suggested that there is no survival differ-
ence between patients with SLNM and those with N0
esophageal squamous cell carcinoma; that is, SLNM does
not affect the prognosis [12]. Bardia et al. [13] reported
that six rectal adenocarcinoma patients with a solitary in-
guinal LN metastasis survived a mean of 42 months from
diagnosis, three of the six patients still being alive after a
mean duration of 40 months of follow-up when the article
was accepted for publication. It is important to investigate
the prognosis of patients with SLNM; the presence of
multiple LN metastases is already known to be associated
with systematic disease and poor prognosis [14]. However,
thus far no studies have investigated the prognosis of CC
patients with SLNM.In this study we analyzed the SEER data of 86,674 CC
patients and found significant differences in survival be-
tween patients with SLNM and those with pN1b disease,
verifying our hypothesis that SLNM is the earliest form of
LN invasion and has heterogeneous outcomes. Soni et al.
confirmed the sentinel node as the only site of metastasis
in 41% of node-positive patients [10] and considered that
the patients with SLNM did not have systemic disease. We
further investigated survival differences by T stage category
and found that patients with SLNM in all five pT stages
had a significantly longer 5-year CCSS than did pN1b
patients, indicating that CC with a SLNM may have an
inherently favorable biologic character.
Of interest is that, in our study, the 5-year CCSS of pa-
tients with pT1N1a CC was 92.6%, which is higher than
Table 6 Univariate and multivariate survival analyses by pN stage in patients with pT4b stage CC
Univariate analysis Multivariate analysis
Variable 5-year CCS Log rank χ2 test P HR (95% CI) P
Years of diagnosis 37.575 <0.001 0.001
1988-1993 44.4% Reference
1994-1999 49.2% 0.905 (0.807-1.014)
2000-2003 55.7% 0.809 (0.726-0.902)
Sex 1.163 0.281 NI
Male 51.9%
Female 50.7%
Age 41.821 <0.001 <0.001
<60 56.7% Reference
≥60 48.0% 1.329 (1.213-1.456)
Race 19.460 <0.001 <0.001
White 52.0% Reference
Black 42.3% 1.337 (1.175-1.522)
Othera 56.4% 0.920 (0.781-1.084)
Grade 48.208 <0.001 <0.001
High/moderate 54.3% Reference
Poor/anaplastic 44.8% 1.343 (1.219-1.479)
Unknown 41.7% 1.324 (1.094-1.601)
Histotype 0.024 0.877 NI
Adenocarcinoma 51.2%
Mucinous/signet ring cell 51.4%
No. of LNs dissected 158.496 <0.001 <0.001
<12 42.4% Reference
≥12 60.4% 0.598 (0.548-0.653)
LNs status 1213.378 <0.001 <0.001
N0 (pIIC) 60.6% 0.596 (0.534-0.666)
N1a 40.5% Reference
N1b 34.1% 1.201 (1.062-1.358)
aOther includes American Indian/Alaska native, Asian/Pacific Islander, and unknown.
NI: not included in multivariate survival analyses.
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tients with pT1-2N1a stage was similar to that of those
with stage pIIA, but significantly greater than that of those
with pIIB disease. Patients with pT3-4N1a disease had a
better 5-year CCSS than those with pIIC. What could ex-
plain why patients with SLNM have a better CCSS than
those with no LN metastases? We postulate that the major
reasons are incomplete surgical resection and/or inad-
equate node sampling, resulting in inaccurate TNM sta-
ging. In the United States, more than 60% of colon cancer
is under-staged after surgery [15]. At least 12 examined
LNs is the benchmark for accurately ascertaining patho-
logical node stage. Numerous observational studies of the
impact of the number of LNs retrieved in patients with
CC have shown a clear survival benefit with increasingnumbers of LNs examined, especially in stage II patients
[16-18]; our findings are consistent with these data. The
more nodes that are examined and found negative, the more
likely that a stage II patient is really node-negative, whereas
lower nodal counts increase the risk that a node-positive pa-
tient will be misclassified as node-negative. When the tech-
nique of sentinel lymph node mapping is used, there is a
15% absolute increase in nodal positivity [10]. Such under-
staging leads to under-treatment: many under-staged pa-
tients do not receive the adjuvant chemotherapy that is
essential for survival benefit. About 15% to 20% of stage I/II
colon patients develop recurrence within 5 years of diagno-
sis [19]. The benefits of increased nodal counts in node-
positive patients remain controversial. Because we used the
number of LNs dissected as a co-variable in our univariate
Table 7 Comparison of 5-year CCSS of patients with SLNM and pII stage CC
Variable HR (95% CI) P HR (95% CI) P HR (95% CI)
pTNM stage <0.001 <0.001 <0.001
IIA Reference 0.723 (0.688-0.759) <0.001 0.271 (0.252-0.290) <0.001
IIB 1.384 (1.317-1.453) <0.001 Reference 0.374 (0.350-0.401) <0.001
IIC 3.695 (3.443-3.966) <0.001 2.671 (2.495-2.859) <0.001 Reference
T1-2N1a 0.937 (0.838-1.049) 0.259 0.677 (0.606-0.757) <0.001 0.254 (0.224-0.287) <0.001
T3-4aN1a 2.221 (2.109-2.339) <0.001 1.605 (1.529-1.685) <0.001 0.601 (0.560-0.645) <0.001
T4bN1a 6.506 (5.886-7.192) <0.001 4.703 (4.262-5.189) <0.001 1.761 (1.576-1.966) <0.001
T1-2N1b 1.344 (1.189-1.518) <0.001 0.971 (0.861-1.096) 0.634 0.364 (0.319-0.414) <0.001
T3-4aN1b 3.060 (2.915-3.211) <0.001 2.212 (2.115-2.312) <0.001 0.828 (0.774-0.886) <0.001
T4bN1b 8.011 (7.328-8.757) <0.001 5.790 (5.307-6.317) <0.001 2.168 (1.961-2.397) <0.001
P values refer to comparison between each group and the reference group and were adjusted for year of diagnosis, age, sex, pathological grading, histological
type of tumor, and number of LNs dissected as covariates.
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SLNM CC has inherently favorable biologic behavior.
Despite this, patients with positive LNs are routinely re-
ferred for adjuvant therapy [20]. NCCN guidelines (version
I.2014) recommend adjuvant chemotherapy for stage pIII
CC patients, including those with stage pT1-2N1a, but do
not recommend adjuvant chemotherapy for stage pII pa-
tients who are assessed as low risk. Many physicians assume
that pII stage patients have a better CCSS than pIII patients.
Also patients with pII stage are less willing to undergo
chemotherapy than pIII stage patients in clinical practice
[21,22]. Thus, stage pT1-2N1a CC patients may be over-
treated and stage pII patients under-treated. Unfortunately,
because information about chemotherapy is not available in
the SEER database, we were not able to analyze this issue
further. Postoperative adjuvant treatment with fluorouracil
and levamisole reportedly reduces the mortality rate by more
than 30% in patients with stage III CC [23-25]. However,
with CCSS as high as 92.6% in patients with pT1N1a stage
disease, does adjuvant chemotherapy benefit all patients in
this subgroup? AJCC staging was initiated to assess survival
and guide clinical practice; we believe it should emphasize
the distinctive characteristics of patients with SLNM.
Although this is a large population-based study evaluat-
ing the subgroup of CC patients with SLNM, it has several
potential limitations. First, the SEER database lacks data
concerning several important tumor characteristics (e.g.,
perineural and lymphovascular invasion), chemotherapy
(neoadjuvant and adjuvant), and patient outcome (recur-
rence and metastasis). Thus, our analyses could not adjust
for these potential confounding factors. Second, there may
be minor misclassification of pT4 stage. In the first years of
this century, the AJCC defined pT4a as CCs infiltrating ad-
jacent organs or structures without perforation of visceral
peritoneum and pT4b as those perforating the visceral peri-
toneum [26]. However, in the 7th AJCC edition, a CC is
classified as pT4a when it infiltrates the serosa and as pT4bwhen it infiltrates adjacent organs: this may influence the
classification of pT4a and T4b CCSS. Third, because SEER
data provide no information about the distribution of
SLNM, we could not tell whether a SLNM was a skip me-
tastasis and therefore could not ascertain whether there is a
difference in survival between skip and no skip groups.
Conclusion
In conclusion, our study shows that patients with SLNM
have a better 5-year CCSS than patients with pN1b disease.
Patients with pT1-2N1a stage and those with p IIA have a
similar 5-year CCSS. Patients with pT3-4aN1a stage have a
higher 5-year CCSS rate than those with pIIC disease. The
overwhelming advantage in long-term survival of CC pa-
tients with SLNM over those with pN1b stage warrants care-
ful attention in clinical practice and TNM stage revision.
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